학술논문
APOEε4 potentiates amyloid β effects on longitudinal tau pathology
Document Type
Author
Ferrari-Souza, J. P.; Bellaver, B.; Ferreira, P. C. L.; Lessa Benedet, Andréa; Povala, G.; Lussier, F. Z.; Leffa, D. T.; Therriault, J.; Tissot, C.; Soares, C.; Wang, Y. T.; Chamoun, M.; Servaes, S.; Macedo, A. C.; Vermeiren, M.; Bezgin, G.; Kang, M. S.; Stevenson, J.; Rahmouni, N.; Pallen, V.; Poltronetti, N. M.; Cohen, A.; Lopez, O. L.; Klunk, W. E.; Soucy, J. P.; Gauthier, S.; Souza, D. O.; Triana-Baltzer, G.; Saad, Z. S.; Kolb, H. C.; Karikari, Thomas; Villemagne, V. L.; Tudorascu, D. L.; Ashton, Nicholas J.; Zetterberg, Henrik, 1973; Blennow, Kaj, 1958; Zimmer, E. R.; Rosa-Neto, P.; Pascoal, T. A.
Source
Nature Aging. 3(10)
Subject
Language
English
ISSN
2662-8465
Abstract
The mechanisms by which the apolipoprotein E epsilon 4 (APOE epsilon 4) allele influences the pathophysiological progression of Alzheimer's disease (AD) are poorly understood. Here we tested the association of APOE epsilon 4 carriership and amyloid-beta (A beta) burden with longitudinal tau pathology. We longitudinally assessed 94 individuals across the aging and AD spectrum who underwent clinical assessments, APOE genotyping, magnetic resonance imaging, positron emission tomography (PET) for A beta ([F-18]AZD4694) and tau ([F-18]MK-6240) at baseline, as well as a 2-year follow-up tau-PET scan. We found that APOE epsilon 4 carriership potentiates A beta effects on longitudinal tau accumulation over 2 years. The APOE epsilon 4-potentiated A beta effects on tau-PET burden were mediated by longitudinal plasma phosphorylated tau at threonine 217 (p-tau217(+)) increase. This longitudinal tau accumulation as measured by PET was accompanied by brain atrophy and clinical decline. Our results suggest that the APOE epsilon 4 allele plays a key role in A beta downstream effects on the aggregation of phosphorylated tau in the living human brain.